ADF (Actin Depolymerizing Factor) inhibitors are a class of chemical compounds that play a pivotal role in the regulation of cytoskeletal dynamics within cells. The actin cytoskeleton is a complex network of protein filaments that provides structural support and facilitates various cellular processes, including cell motility, division, and shape maintenance. ADF proteins are key regulators of actin dynamics as they modulate the polymerization and depolymerization of actin filaments. ADF inhibitors, as the name suggests, are substances that impede the function of ADF proteins, thereby affecting the dynamic assembly and disassembly of actin filaments.
These inhibitors typically target ADF proteins by binding to specific regions of these proteins or by interfering with their enzymatic activity. By doing so, they disrupt the delicate balance between actin polymerization and depolymerization, leading to alterations in the cytoskeletal structure and cellular morphology. ADF inhibitors are invaluable tools in cell biology research, as they allow scientists to manipulate and study the actin cytoskeleton's dynamics with precision. Understanding the role of ADF inhibitors in controlling actin dynamics can provide insights into fundamental cellular processes, such as cell migration, cell division, and cell signaling. Additionally, this knowledge can have broader implications in fields like cancer biology, neurobiology, and developmental biology, where actin dynamics are critical for normal cellular function.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ticagrelor | 274693-27-5 | sc-472972 sc-472972A sc-472972B sc-472972C | 10 mg 25 mg 50 mg 100 mg | $104.00 $228.00 $270.00 $302.00 | ||
Blocks the P2Y12 receptor on platelets, preventing platelet activation and aggregation, thus inhibiting clot formation. | ||||||
Clopidogrel | 113665-84-2 | sc-507403 | 1 g | $122.00 | 1 | |
After conversion in the liver, it irreversibly inhibits the P2Y12 receptor, reducing platelet activation and aggregation. | ||||||
Prasugrel | 150322-43-3 | sc-391536 | 100 mg | $79.00 | ||
Similar to clopidogrel, it's metabolized to an active form that irreversibly inhibits the P2Y12 receptor on platelets. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Increases levels of cAMP, inhibiting platelet activation, and also dilates blood vessels to reduce clot formation. | ||||||
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | $158.00 | 18 | |
Blocks the active site of factor Xa, reducing thrombin formation and preventing blood clot formation. | ||||||
Apixaban | 503612-47-3 | sc-364406 sc-364406A | 10 mg 50 mg | $240.00 $634.00 | 2 | |
Selectively inhibits factor Xa, thereby reducing the conversion of prothrombin to thrombin and inhibiting clot formation. | ||||||
Edoxaban | 480449-70-5 | sc-483508 | 25 mg | $522.00 | ||
Similar to apixaban, it specifically inhibits factor Xa to prevent thrombin generation and blood clot formation. | ||||||
Fondaparinux | 104993-28-4 | sc-507424 | 10 mg | $297.00 | ||
Binds to antithrombin III, enhancing its ability to inhibit factor Xa and preventing thrombin formation. | ||||||
Argatroban | 74863-84-6 | sc-201310 sc-201310A | 10 mg 50 mg | $117.00 $469.00 | 13 | |
Directly inhibits thrombin (factor IIa), preventing the conversion of fibrinogen to fibrin and clot formation. | ||||||
Bivalirudin | 128270-60-0 | sc-278793 | 5 mg | $110.00 | ||
Also a direct thrombin inhibitor, it binds to and inhibits thrombin's activity, preventing clot formation. | ||||||